ArticleScientific reports2025
The vitamin D spectrum: insights into 25(OH)D and VDBP in chronic kidney disease and post-transplant.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From the Vitamin D Paradox to Precision Nutrition: Targeted Supplementation, Assay Pitfalls, and Clinical Decision-Making.Current nutrition reports · 2026Review
- Vitamin D3 and Body Composition Association with Graft Function in Long-Term Kidney Transplant Recipients.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
CKD progression is associated with declining vitamin D levels, which correlate with various comorbidities. Total serum 25-hydroxyvitamin D (Total-25(OH)D) may not accurately reflect vitamin D deficiency in these patients. This study aimed to evaluate the vitamin D spectrum in CKD and kidney transplant recipients (KTRs). We recruited 38 stage 3 & 4 CKD patients and 38 patients with ESRD, who were followed for six-months post-KT. Total-25(OH)D and VDBP were measured using ELISA. Free and bioavailable-25(OH)D concentrations were calculated using Bikle formula. ESRD patients had lower total-25(OH)D, free-25(OH)D, and bioavailable-25(OH)D, compared to stage 3 & 4 CKD patients. VDBP levels showed no significant difference. Six months post-KT, a continued decline in free and bioavailable-25(OH)D was observed, whilst VDBP was increased. No significant change was found in total-25(OH)D levels. On regression analysis, bioavailable-25(OH)D and creatinine could independently predict CKD stage (based on eGFR). Total-25(OH)D, free-25(OH)D, and bioavailable-25(OH)D showed significant decline, with increasing severity of CKD. Notably, even after KT, they did not show significant improvement. Elevated VDBP post-KT probably contributed to continued decline in free and bioavailable-25(OH)D. Further research with extended follow-up is warranted to assess whether these alterations have a significant impact on long-term patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.